Patents Examined by Bao Q Li
  • Patent number: 11952406
    Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A?) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of A? and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (A?) peptide and a tau peptide.
    Type: Grant
    Filed: June 2, 2023
    Date of Patent: April 9, 2024
    Assignee: OTHAIR PROTHENA LIMITED
    Inventors: Robin Barbour, Gene Kinney, Wagner Zago, Tarlochan S. Nijjar
  • Patent number: 11945855
    Abstract: Recombinant polypeptides comprising a modified DR?1 domain are provided. In some embodiments, the polypeptides include the modified DR?1 domain, an antigenic peptide, and optionally a linker sequence. Pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said recombinant polypeptides or pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides are also provided.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: April 2, 2024
    Assignees: Oregon Health & Science University, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Roberto Meza-Romero, Arthur A. Vandenbark, Halina Offner
  • Patent number: 11944677
    Abstract: This invention relates to chimeric virus-like particles (VLPs) assembled from a polypeptide comprising a papilloma virus (PV) L1 protein or L1/L2 protein and a target peptide comprising a CD8+ T cell epitope derived from a human pathogen. This invention also relates to methods using the chimeric VLPs as antigen-specific redirectors of immune responses.
    Type: Grant
    Filed: March 25, 2022
    Date of Patent: April 2, 2024
    Assignee: VERIMMUNE INC.
    Inventors: Joshua Weiyuan Wang, Nattha Ingavat
  • Patent number: 11921114
    Abstract: Alternative antibodies to screen for SARS-CoV-2 are disclosed. One alternative antibody is Mouse Species Coronavirus (COVID-19, MERS, and SARS-CoV NP) Antibody, Catalog Number HM1056 (“E3-Antibody” or “E3”), from EastCoast Bio, Inc., PO Box 489, North Berwick, ME 03906, USA (“EastCoast Bio”). Another alternative antibody is a combination of the E3-Antibody and Mouse Species Coronavirus (COVID-19, MERS, and SARS-CoV NP) Antibody, Catalog Number HM1057 (“E1-Antibody” or “E1”), from EastCoast Bio (the combination of the E1-Antibody and the E3-Antibody is designated as “E1/E3-Antibody” or simply “E1/E3”).
    Type: Grant
    Filed: June 2, 2021
    Date of Patent: March 5, 2024
    Inventors: Melicia R. Gainey, Dalia Natour
  • Patent number: 11896666
    Abstract: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: February 13, 2024
    Assignee: Zoetis Services LLC
    Inventors: Paul Joseph Dominowski, Ramasamy Mannar Mannan, Richard Lee Krebs, James Richard Thompson, Tedd Alan Childers, Mary Kathryn Olsen, Robert John Yancey, Jr., Risini Dhammika Weeratna, Shucheng Zhang, Cedo Martin Bagi
  • Patent number: 11883484
    Abstract: The present invention relates to compositions comprising two or more DNA plasmids encoding consensus and transmitted founder HIV envelope glycoproteins which expressed and induce a potent immune response.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: January 30, 2024
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology
    Inventors: David Weiner, Megan Wise
  • Patent number: 11844834
    Abstract: There is provided a novel vaccine adjuvant, and more specifically, a vaccine adjuvant for stimulating a T lymphocyte-specific immune response, which includes an IL-12 protein and an IL-21 protein as active ingredients, or includes the polynucleotide encoding an IL-12 protein and the polynucleotide encoding an IL-21 protein as active ingredients.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: December 19, 2023
    Assignee: SL VAXIGEN, INC.
    Inventors: Yong Bok Seo, Youngwoo Choi, Sang Hee Sim
  • Patent number: 11820796
    Abstract: Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: November 21, 2023
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Lucy Rutten, Daphné Truan, Nika Mindy Strokappe, Johannes Petrus Maria Langedijk
  • Patent number: 11807872
    Abstract: Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus may also stabilize co-expressed hemagglutinins so that the hemagglutinins do not undergo mutation or decrease the need for HA binding to cells.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: November 7, 2023
    Assignees: Wisconsin Alumni Research Foundation (WARF), The University of Tokyo
    Inventors: Yoshihiro Kawaoka, Shinya Yamada, Shiho Chiba
  • Patent number: 11793871
    Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. The vaccines comprise nanoparticles that display HA trimers from Group 2 influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to stabilized stem regions of Group 2 influenza virus HA proteins. The fusion proteins self-assemble to form the HA-displaying nanoparticles. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.
    Type: Grant
    Filed: May 11, 2022
    Date of Patent: October 24, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey C. Boyington, Barney S. Graham, John R. Mascola, Hadi M. Yassine, Kizzmekia S. Corbett, Syed M. Moin, Lingshu Wang, Masaru Kanekiyo
  • Patent number: 11780931
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: October 10, 2023
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America, as represented by the Secretary, Department of Health and Human Services, The Regents of the University of California
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • Patent number: 11780886
    Abstract: The present invention relates to production of parvoviral vectors to produce adeno-associated virus (AAV) for gene therapy. In particular the invention relates to improvements in parvoviral vectors that increase the packaging capacity, production efficiency, and infectivity of AAV virions that is necessary for large scale manufacturing of AAV for clinical purposes.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: October 10, 2023
    Assignee: uniQure IP B.V.
    Inventor: David Johannes Francois Du Plessis
  • Patent number: 11771761
    Abstract: Quil-A chitosan spherical nanostructure complexes as well as methods of making and using such complexes are disclosed herein. Also provided are Quil-A chitosan spherical nanostrucutres loaded with one or more RNA, DNA, or protein payload molecules as well as methods of making and using such loaded complexes.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: October 3, 2023
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Adel M. Talaat, Shaswath Chandrasekar
  • Patent number: 11773148
    Abstract: The present disclosure is directed to individual peptide immunogen constructs targeting portions of the Tau protein for the treatment and/or prevention of tauopathies. The present disclosure is also directed to compositions containing the peptide immunogen constructs, methods of making and using the peptide immunogen constructs, and antibodies produced by the peptide immunogen constructs.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: October 3, 2023
    Assignees: UNITED NEUROSCIENCE, UNS IP HOLDINGS, LLC
    Inventor: Chang Yi Wang
  • Patent number: 11766474
    Abstract: The present disclosure provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to an immunoresponsive cell comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)), and expressing increased level of IL-36. In certain embodiments, the engineered immunoresponsive cells are antigen-directed and have enhanced immune-activating properties.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: September 26, 2023
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Anthony Daniyan, Renier J. Brentjens
  • Patent number: 11759512
    Abstract: Nucleic acids encoding modified norovirus VP1 proteins, and VLPs comprising one or more of the modified norovirus VP1 proteins are provided. Methods for modified norovirus VP1 protein, and norovirus VLP, production in plants, portions of the plant or a plant cell, are also described.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: September 19, 2023
    Assignee: MEDICAGO INC.
    Inventors: Marc-Andre D'Aoust, Pierre-Olivier Lavoie
  • Patent number: 11759513
    Abstract: Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: September 19, 2023
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Baoming Jiang, Yuhuan Wang
  • Patent number: 11739303
    Abstract: Modified influenza virus neuraminidases are described herein that have stabilized NA tetramers which may improve vaccine production efficiency, thus improving the yield of vaccine viruses.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: August 29, 2023
    Assignees: Wisconsin Alumni Research Foundation (WARF), The University of Tokyo
    Inventors: Yoshihiro Kawaoka, Yuri Furusawa, Seiya Yamayoshi
  • Patent number: 11738058
    Abstract: A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: August 29, 2023
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Linde Miles, John Poirier, Charles Rudin
  • Patent number: 11723964
    Abstract: The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding a tumor-associated antigen and an administration of an antibody to a cancer patient.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: August 15, 2023
    Assignee: Bavarian Nordic A/S
    Inventors: Hubertus Hochrein, Henning Lauterbach, José Medina Echeverz, Matthias Habjan